Oryzon Genomics SA BME:ORY:
COMPLETED THE ACCELERATED BOOKBUILD OFFERING
EFFECTIVE AMOUNT OF THE CAPITAL INCREASE: 12.0 MILLION EUROS.
ISSUE PRICE: 2.70 EUROS PER SHARE, OF WHICH 0.05 EUROS CORRESPOND TO NOMINAL VALUE AND 2.65 EUROS TO SHARE PREMIUM.
ISSUE PRICE REPRESENTS A 12.68% DISCOUNT ON CLOSING PRICE OF COMPANY’S SHARES AS OF JUNE 30, 2026
NOMINAL AMOUNT OF THE CAPITAL INCREASE 222,222 EUROS
CAPITAL INCREASE REPRESENTS 5.56% BEFORE, 5.27% AFTER INCREASE